ABVX · Nasdaq, OTC · CIK 0001956827

Abivax S.A.

Abivax S.A.’s most recent SEC filing in our snapshot is a Form 6-K filed on Sep 21, 2026. Its EDGAR record lists 0 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-EUR 336.1M
Form 4 filings on record, past 12 months
0

Company overview

Legal name (as filed)
Abivax S.A.
Tickers
ABVX, AAVXF
SEC Central Index Key (CIK)
0001956827
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
PARIS
State or country of incorporation
France
Fiscal year ends
December 31
SEC filer category
Accelerated filer<br>Emerging growth company
Position in SEC ticker list
#1049 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Abivax S.A.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in EUR; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-EUR 42.5MFY2021-EUR 60.7MFY2022-EUR 147.7MFY2023-EUR 176.2MFY2024-EUR 336.1MFY2025
ABVX annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue—————
Net income-EUR 42.5M-EUR 60.7M-EUR 147.7M-EUR 176.2M-EUR 336.1M
Diluted EPS-EUR 2.75-EUR 3.18-EUR 3.43-EUR 2.80-EUR 4.83
Total assetsEUR 109.2MEUR 75.5MEUR 327.1MEUR 205.2MEUR 584.3M
Cash and equivalentsEUR 60.7MEUR 26.9MEUR 233.8MEUR 57.0MEUR 38.1M

XBRL tags used: netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

ABVX latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 23, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Sep 21, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Abivax S.A., by form type:

6-K ×13SCHEDULE 13G/A ×6SCHEDULE 13D/A ×5424B5 ×4FWP ×4144 ×2F-6EF ×1POSASR ×1424B7 ×120-F ×1S-8 ×1F-3ASR ×1
ABVX recent filings
FiledFormWhat it isOriginal
Sep 21, 20266-KReport of a foreign private issuer· period Jun 30, 2026Document · Index
Sep 21, 2026F-6EFF-6EFDocument · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 6, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jul 2, 20266-KReport of a foreign private issuer· period Jul 2, 2026Document · Index
Jul 2, 2026424B5424B5Document · Index
Jul 1, 2026FWPFWPDocument · Index
Jun 30, 2026FWPFWPDocument · Index
Jun 30, 2026424B5424B5Document · Index
Jun 30, 2026POSASRPOSASRDocument · Index
Jun 29, 20266-KReport of a foreign private issuer· period Jun 29, 2026Document · Index
Jun 2, 20266-KReport of a foreign private issuer· period Jun 1, 2026Document · Index
May 22, 20266-KReport of a foreign private issuer· period Mar 31, 2026Document · Index
May 20, 20266-KReport of a foreign private issuer· period May 20, 2026Document · Index
May 11, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
May 7, 20266-KReport of a foreign private issuer· period May 7, 2026Document · Index
May 7, 2026424B7424B7Document · Index
Apr 20, 20266-KReport of a foreign private issuer· period Apr 20, 2026Document · Index
Mar 23, 202620-FAnnual report of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 23, 20266-KReport of a foreign private issuer· period Dec 31, 2025Document · Index
Mar 23, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Feb 23, 20266-KReport of a foreign private issuer· period Feb 21, 2026Document · Index
Feb 13, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jan 14, 2026SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jan 8, 2026144Notice of proposed sale of securitiesDocument · Index
Dec 15, 20256-KReport of a foreign private issuer· period Sep 30, 2025Document · Index
Nov 14, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Nov 14, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Oct 30, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Oct 28, 2025144Notice of proposed sale of securitiesDocument · Index
Sep 8, 20256-KReport of a foreign private issuer· period Jun 30, 2025Document · Index
Aug 14, 2025SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Jul 31, 2025SCHEDULE 13D/AActive beneficial ownership report (over 5%)Document · Index
Jul 24, 2025424B5424B5Document · Index
Jul 24, 20256-KReport of a foreign private issuer· period Jul 24, 2025Document · Index
Jul 24, 2025FWPFWPDocument · Index
Jul 23, 2025FWPFWPDocument · Index
Jul 23, 2025424B5424B5Document · Index
Jul 23, 2025F-3ASRF-3ASRDocument · Index

Insider filing activity

0 Form 4 filings appear in Abivax S.A.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001956827 and XBRL company facts. Abivax S.A. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.